Is Elutia Stock a good buy in 2025, according to Wall Street analysts?
The consensus among 1 Wall Street analyst covering (NASDAQ: ELUT) stock is to Strong Buy ELUT stock.
Out of 1 analyst, 1 (100%) are recommending ELUT as a Strong Buy, 0 (0%) are recommending ELUT as a Buy, 0 (0%) are recommending ELUT as a Hold, 0 (0%) are recommending ELUT as a Sell, and 0 (0%) are recommending ELUT as a Strong Sell.
What is ELUT's earnings growth forecast for 2025-2025?
(NASDAQ: ELUT) Elutia's forecast annual earnings growth rate of N/A is not forecast to beat the US Medical Devices industry's average forecast earnings growth rate of N/A, and while it is not forecast to beat the US market's average forecast earnings growth rate of N/A.
Elutia's earnings in 2025 is -$53,949,000.
In 2025, ELUT is forecast to generate -$30,552,666 in earnings, with the lowest earnings forecast at -$30,552,666 and the highest earnings forecast at -$30,552,666.
What is ELUT's forecast return on equity (ROE) for 2025-2025?
(NASDAQ: ELUT) forecast ROE is N/A, which is considered weak.
What is ELUT's Price Target?
According to 1 Wall Street analyst that have issued a 1 year ELUT price target, the average ELUT price target is $8.00, with the highest ELUT stock price forecast at $8.00 and the lowest ELUT stock price forecast at $8.00.
The Wall Street analyst predicted that Elutia's share price could reach $8.00 by Mar 7, 2026. The average Elutia stock price prediction forecasts a potential upside of 247.83% from the current ELUT share price of $2.30.
What is ELUT's Earnings Per Share (EPS) forecast for 2025-2025?
(NASDAQ: ELUT) Elutia's current Earnings Per Share (EPS) is -$1.86. In 2025, ELUT's EPS is forecast to hit -$0.75 (min: -$0.75, max: -$0.75).
What is ELUT's forecast return on assets (ROA) for 2025-2025?
(NASDAQ: ELUT) forecast ROA is -84.57%, which is lower than the forecast US Medical Devices industry average of 9.53%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.